MYND Life Sciences Announces DTC Eligibility

MYND Life Sciences Inc.(CNSX: MYND) (OTC: MYNDF) is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals and vaccines is pleased to announce that it is now eligible for Depository Trust Company (“DTC”) services in relation to the Company’s listing on the OTC. Through the OTC listing, investors from the United States may more easily trade MYNDF stock, in addition to MYND’s listing on the CSE “MYND” in Canada.

We are excited to receive DTC eligibility, which not only provides the Company with access to a broader range of US-based investors but also provides additional opportunities for investors in the US to acquire MYND shares. There are 300 million persons world-wide suffering from major depressive disorder and other related conditions who have not been well-served by the existing class of SSRIs to treat depression.  We are convinced we have the scientific capacity, the intellectual property and the right leadership to achieve the first substantive innovation in this drug class in a generation.

MYND CEO, Dr. Lyle Oberg

DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manages the electronic clearing and settlement of publicly-traded companies. MYND is now eligible to be electronically cleared and settled, which will streamline the process of trading, enhance liquidity, and provide direct access to investors in the United States OTC capital markets

To view the original press release in its entirety click here